In brief: Shingles vaccine shows promise in large trial
In brief
Shingles vaccine shows promise in large trial
If approved by the FDA, a vaccine for shingles could be available in doctors’ offices in spring 2006. That’s the word from Merck & Co., the vaccine’s developer, after a large controlled trial showed that it reduced the chances of getting shingles by 51% in healthy adults over age 60. Moreover, the vaccine cut the incidence of postherpetic neuralgia by two-thirds. Postherpetic neuralgia is a complication of shingles that can result in chronic pain lasting a year or more.
The classic symptoms of shingles (herpes zoster) are a blistering rash and pain, usually on one side of the face or trunk. The disease is caused by the varicella-zoster virus; the most common way that people are exposed to it is through childhood chickenpox. After the initial infection, the virus lies dormant in nerve cells. Later in life, when the immune system is less able to keep it in check, the virus can resurface, producing shingles. Not everyone who’s had chickenpox will get shingles, but by age 85, about half will.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.